-
Medtronic's Spine Division Continues To Lag The Market
Tuesday, June 7, 2016 - 11:05am | 273Medtronic PLC (NYSE: MDT) provided further details regarding its revenue and EPS growth plan, which BTIG’s Sean Lavin views as achievable. Lavin maintains a Neutral rating on the company. Medtronic’s Goals “While we hope MDT hits these goals; with continued pricing pressure and a...
-
Intuitive Surgical Shares Downgraded To Neutral At BTIG
Friday, April 1, 2016 - 11:06am | 188BTIG issued a note on Intuitive Surgical Inc. (NASDAQ: ISRG) after recent analysis showed limited share appreciation in the near term due to a high valuation. Analysts downgraded Intuitive Surgical to Neutral while a price target is currently unavailable. Analysts Sean Lavin and Karen Koski...
-
Promising Zika Research Fuels Cerus Stock Surge
Thursday, January 28, 2016 - 4:54pm | 468Shares of Cerus Corporation (NASDAQ: CERS) were trading up 4.2 percent Thursday as news of research that successfully inactivated the Zika virus in human blood circulated among traders. BTIG analysts Karen Koski, Dr. Sean Lavin and Andrea Alfonso reiterated their "buy" rating for...
-
Everyone's Talking About ROLARR Heading Into Intuitive Surgical Earnings: Here's What It Means
Tuesday, July 21, 2015 - 1:31pm | 814Intuitive Surgical, Inc. (NASDAQ: ISRG) is scheduled to report its second quarter results after Tuesday's market close. Estimize is expecting the company to earn $4.05 per share (based on 38 estimates) on revenue of $570.82 million. This compares to the Wall Street consensus estimate...
-
UPDATE: BTIG Research Initiates Coverage On Histogenics On NeoCart Potential
Friday, January 23, 2015 - 11:02am | 176In a report published Friday, BTIG Research analyst Sean Lavin initiated coverage on Histogenics Corp. (NASDAQ: HSGX) with a Buy rating and $13.00 price target. In the report, BTIG Research noted, “Histogenics' NeoCart is likely to be the first regenerative tissue implant available in the U.S. with...
-
UPDATE: BTIG Research Downgrades Abiomed As FDA Overhang Is Gone
Monday, November 3, 2014 - 10:47am | 92In a report published Monday, BTIG Research analyst Sean Lavin downgraded the rating on Abiomed, Inc. (NASDAQ: ABMD) from Buy to Neutral. In the report, BTIG Research noted, “We feel shares will trade in the $34-36 range a year from now. We do not see another 15% of upside and move to Neutral...
-
BTIG Likes What It Saw At Intuitive Surgical Conference
Tuesday, October 28, 2014 - 2:17pm | 242In a note from research firm BTIG, Sean Lavin M.D provides insights from the Technology Forum hosted by Intuitive Surgical, Inc. (NASDAQ: ISRG). "The event was oversubscribed: Since this conference is mainly attended by general surgeons, we see this attendance as a lead indicator for...
-
UPDATE: BTIG Upgrades Intuitive Surgical
Wednesday, October 22, 2014 - 9:08am | 164In a note released Wednesday morning, BTIG analyst Sean Lavin upgraded shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) from Neutral to Buy and announced a $585 price target. In light of Intuitive's earnings release on Tuesday, Lavin commented, "Though shares may not trade up a whole...
-
BTIG Equity Research Bullish On Lombard Medical Inc
Thursday, September 18, 2014 - 11:25am | 134Analysts at BTIG Equity Research initiated coverage on Lombard Medical Inc (NASDAQ: EVAR) with a Buy rating and $9 price target Thursday. Sean Lavin highlighted drivers for the firm: The company's innovative Aorfix Stent graft has two significant opportunities. It is the only FDA label...
-
Analysts At BTIG Confident In Endologix Following Meeting With Top Executives
Monday, August 25, 2014 - 3:42pm | 367Sean Lavin of BTIG upgraded shares of Endologix (NASDAQ: ELGX) to Buy. What's notable about the upgrade is that just a few weeks ago on July 7 shares were downgraded to Neutral from Buy. Lavin's decision to return to a Buy rating follows a visit to the company's head office. The analyst notes...
-
BTIG Research: Thoratec 'Drops A Bomb' In Its Second Quarter Results
Thursday, August 7, 2014 - 9:35am | 464Shares of Thoratec (NASDAQ: THOR) were down more than 27 percent during Thursday's pre-market session on robust volume following the company's poor second quarter results reported on Wednesday. Thoratec earned $0.42 per share, in-line with the consensus estimate but revenue declined 9.5...
-
BTIG: Valeant Must Sweeten Allergan Bid To More Than $200/Share
Tuesday, July 22, 2014 - 4:33pm | 215Allergan's (NYSE: AGN) strong showing in its recent second quarter suggests an acquirer may need to offer "north of $200 a share," one analyst said Tuesday. Valeant Pharmaceuticals' (NYSE: VRX) $53 billion unsolicited bid for Allergan was rejected last month. The bid equaled $...
-
UPDATE: BTIG Initiates Coverage On Masimo, Sees 31% Premium To Shares
Tuesday, July 8, 2014 - 12:36pm | 236BTIG analyst Sean Lavin initiated coverage on Masimo (NASDAQ: MASI) with a Buy rating and $32.00 price target. Lavin is optimistic on the medical technology company's future, seeing limited downside for the underperforming stock. The analyst wrote, “We see multiple things that could...
-
UPDATE: BTIG Initiates Coverage On Intuitive Surgical
Tuesday, July 8, 2014 - 9:34am | 225In a note released Tuesday, BTIG Equity Research analyst Sean Lavin M.D. initiated coverage on Intuitive Surgical (NASDAQ: ISRG) with a Neutral rating, but has yet to set a price target. Lavin explained he is optimistic on the long-term outlook of the stock, but sees near-term troubles. He...
-
Wall Street Comfortable With Covidien Buy; Some See Move By Johnson & Johnson
Monday, June 16, 2014 - 4:29pm | 421Wall Street appeared comfortable with the latest big healthcare merger, this one the acquisition of Covidien (NYSE: COV) by Medtronic (NYSE: MDT), a deal which turns eyes to Johnson & Johnson (NYSE: JNJ). "We expect many investors will expect J&J to buy something in the cardiac...